Acute myeloid leukemia (<scp>AML)</scp>‐derived mesenchymal stem cells induce chemoresistance and epithelial–mesenchymal transition‐like program in <scp>AML</scp> through <scp>IL</scp>‐6/<scp>JAK2</scp>/<scp>STAT3</scp> signalingJianle Lu, Li Zhao, Qiaomei Dong et al.|Cancer Science|2023Cited by 46
Rhein exerts anti-multidrug resistance in acute myeloid leukemia via targeting FTO to inhibit AKT/mTORShuling Zhang, Li Zhao, Jianle Lu et al.|Anti-Cancer Drugs|2024Cited by 10
The m6A modulator-mediated cytarabine sensitivity and immune cell infiltration signature in acute myeloid leukemiaJincai Yang, Lanxia Zhou, Liangliang Li et al.|Journal of Cancer Research and Clinical Oncology|2023Cited by 6
PARP3 Promotes AML Progression via Activation of PI3K/AKT/mTOR SignalingTingyong Cao, Li Zhao|Cancers|2025Cited by 1
The FTO inhibitor Rhein is a promising option for the treatment of multidrug resistance AMLShuling Zhang, Li Zhao, Juan Cheng et al.|Research Square|2024Cited by 0